JDRF has entered into a novel research agreement with the Genomics Institute of the Novartis Research Foundation (GNF) to develop therapies for type 1 diabetes.
The four-year partnership, the largest in the history of JDRF, aims to progress a number of potential drug candidates to clinical trials.
According to JDRF International President and CEO Alan Lewis, this new partnership opens exciting new avenues to speed up the translation of basic research into new treatments.
“By creating this interactive collaboration with a world class organization with demonstrated expertise in discovering and developing innovative therapeutics for medical needs, we are looking to expand both the targets and the realm of possible treatments that can benefit people living with diabetes.”
Based in San Diego, the GNF was founded in 1999 and has an impressive track record of translating basic research into clinical outcomes. Their work will directly build on JDRF-funded research and is an exciting evolution of the JDRF research strategy from bench to bedside.
“This partnership provides JDRF access to a highly talented group of scientists, state-of-the-art technology and organization with a proven record of delivering drugs from the clinic to address a critical gap in research,” explains Richard Insel, Executive Vice President of Research at JDRF International.
The initial focus for this partnership will be on the development of new therapies to restore insulin production by re-growing pancreatic beta cells and ensuring their survival, an area of high priority for JDRF.